S629-0299 Screening compound: 3-[4-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N~1~-(4-morpholinophenyl)propanamide

S629-0299 Screening compound: 3-[4-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N~1~-(4-morpholinophenyl)propanamide
S629-0299 Screening compound: 3-[4-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N~1~-(4-morpholinophenyl)propanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound S629-0299
3-[4-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N~1~-(4-morpholinophenyl)propanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

S629-0299

Molecular Formula

C26H31N3O4 (C26 H31 N3 O4)

Compound Name

3-[4-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]-N~1~-(4-morpholinophenyl)propanamide

IUPAC name

3-(4-cyclopropanecarbonyl-2345-tetrahydro-14-benzoxazepin-7-yl)-N-[4-(morpholin-4-yl)phenyl]propanamide

SMILES

O=C(CCc(cc1)cc(C2)c1OCCN2C(C1CC1)=O)Nc(cc1)ccc1N1CCOCC1

InChI

InChI=1S/C26H31N3O4/c30-25(27-22-5-7-23(8-6-22)28-11-14-32-15-12-28)10-2-19-1-9-24-21(17-19)18-29(13-16-33-24)26(31)20-3-4-20/h1,5-9,17,20H,2-4,10-16,18H2,(H,27,30)

InChI Key

VSKFIMRKZFTIFX-UHFFFAOYSA-N

MDL Number (MFCD)

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

449.55

Hydrogen Bond Acceptors Count

6.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

7

Partition Coefficient, logP

3.204

Distribution Coefficient, logD

3.204

Water Solubility, LogSw

-3.34

Polar Surface Area

59.593

Acid Dissociation Constant (pKa)

11.94

Base Dissociation Constant (pKb)

6.79

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

46.15

S629-0299 in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

Allosteric Kinases Inhibitors Library (23117 compounds)

Antiviral Library (67538 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

PPI Helix Turn 3D-Mimetics Library (71298 compounds)

Protein-Protein Interaction Library (218420 compounds)

Beyond the Flatland Library sp3 enriched (92988 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Antiviral
  • Infections
  • Immune system
Targets:
  • Kinases
Mechanism of action:
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Cyclic compounds

References: we are preparing a list of scientific research reports with S629-0299 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound S629-0299?
Check Price and Availability of S629-0299, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of S629-0299 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for S629-0299
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for S629-0299
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of S629-0299 available by request